Clinical Outcomes in Secondary Hyperparathyroidism and the Potential Role of Calcimimetics
Open Access
- 1 January 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 1 (suppl 1) , i29-i35
Abstract
Cinacalcet, a type II calcimimetic agent that interacts with the calcium-sensing receptor on the parathyroid gland and increases its sensitivity to calcium, has proved an effective therapy for the treatment of the biochemical derangements that comprise uraemic secondary hyperparathyroidism. These patients experience high cardiovascular attrition with evidence that this is associated with vascular calcification, arterial stiffening and increased pulse wave velocity, and with some of the disturbances of bone and mineral metabolism in uraemia. Thus, it is possible that improved biochemical control in calcimimetic-treated patients might lead to better clinical outcomes. This hypothesis was investigated by retrospective analyses of randomized placebo-controlled phase 3 studies. The addition of cinacalcet to standard therapy with active vitamin D and phosphate binders was found to result in a 93% reduction in the rate of parathyroidectomy, a 54% reduction in fracture rate and 39% reduction in the rate of cardiovascular hospitalization, as well as improvements in some measures of quality of life. These encouraging results point to the need for a more robust assessment of the impact of cinacalcet on cardiovascular and skeletal outcomes.Keywords
This publication has 51 references indexed in Scilit:
- Calcification and Cardiovascular HealthHypertension, 2006
- Cinacalcet: An oral calcimimetic agent for the managementof hyperparathyroidismClinical Therapeutics, 2005
- Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidismNephrology Dialysis Transplantation, 2005
- Regulation of Vascular CalcificationCirculation Research, 2005
- Stiffness of Capacitive and Conduit ArteriesHypertension, 2005
- Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidismKidney International, 2005
- Validation of the Kidney Disease Quality of Life (KDQOL) Cognitive Function subscaleKidney International, 2004
- Aortic pulse wave velocity index and mortality in end-stage renal diseaseKidney International, 2003
- Arterial Calcifications, Arterial Stiffness, and Cardiovascular Risk in End-Stage Renal DiseaseHypertension, 2001
- Matrix Gla Protein Is Regulated by a Mechanism Functionally Related to the Calcium-Sensing ReceptorBiochemical and Biophysical Research Communications, 2000